Nuvarande VD för Moberg Pharma AB och tidigare erfarenhet från befattningar som CFO på Athera Biotechnologies AB, Moberg Pharma AB och Lipopeptide

Athera Biotechnologies announces that first dosing in a multiple dosing study in healthy volunteers has been done with its fully human antibody PC-mAb, less than …

Taggar: Pågående uppdrag: Styrelseordförande i Athera Biotechnologies AB. Styrelseledamot i Olsson Solutions AB, IRLAB Sweden, Gesynta Pharma AB, European Society of Cardiology och Hjärt-Lungfonden Svenska Nationalföreningen mot hjärt- och lungsjukdomar. Aktieinnehav: 2 000 A-aktier. 2019-05-21 About Athera Biotechnologies . Athera develops anti-inflammatory medicine to treat vascular disease and conditions with major medical requirements, with a focus on the pharmaceutical candidate ATH3G10. The main shareholders are Industrifonden, Östersjöstiftelsen and Linc AB. Athera has just now completed a new share issue with Sciety. Stockholm December 3, 2015 Athera Biotechnologies AB, a privately held biopharmaceutical company focused on developing a new antibody against cardiovascular diseases, has completed a 24 million SEK financing from a consortium led by The Foundation for Baltic and East European Studies (Östersjöstiftelsen), Industrifonden and Linc Invest. Athera Biotechnologies AB - Org.nummer: 5566206859.

Aktieinnehav: 2 000 A-aktier. , adress mm för Athera Biotechnologies AB. En fullständig upplysning med all information som UC har om bolaget och med en kreditbedömning i form av UC:s unika Riskklass och Riskprognos samt en rekommenderad kreditlimit. Athera Biotechnologies utvecklar en läkemedelskandidat för en indikation inom hjärt-kärlsjukdomar där det idag saknas tillräcklig behandling. Efter framgångsrika fas 1-studier har nu bolaget rest kapital för att genomföra en klinisk fas 2-studie varpå förvärv från ett större läkemedelsbolag förväntas. pharmaceutical area, such as the case of Athera Biotechnologies AB 6. It will be very interesting to look into one small company like Athera and one big like AstraZeneca and see the differences and similarities in their organizational strategies concerning innovation and entrepreneurship.

AstraZeneca AB, http://astrazeneca.se. Athera Biotechnologies AB, http://www.athera.se. Atnahs Pharma Nordics A/S. Atossa Therapeutics, Inc.

Clinical stage development of anti-inflammatory antibody therapeutics for treatment of immunovascular disease. Athera is a clinical stage biopharmaceutical Apr 2, 2020 Athera Biotechnologies AB, a Swedish biopharmaceutical developer of therapeutic antibodies, announced that the last patient has been dosed Athera Biotechnologies is a clinical-stage biopharmaceutical company focused on developing targeted anti-inflammatory biological candidate drugs for the Athera has a unique and in-depth understanding of the immunological components in atherosclerosis, the inflammatory process leading to cardiovascular Phosphorylcholine fully human monoclonal antibody (PC-mAb), is being developed by Athera Biotechnologies, a part of the Karolinska Development portfolio With its lead candidate, ATH3G10, a first-in-class antibody indicated for large ST- elevation myocardial infarction (STEMI), Athera Biotechnologies is harnessing Feb 28, 2018 Athera Biotechnologies announces that a composition of matter patent covering antibodies with binding to phosphorylcholine, PC has been Sponsor: Athera Biotechnologies AB. Information provided by (Responsible Party ):.

Sciety-nätverket investerar i Athera Biotechnologies tillsammans med Industrifonden, Östersjöstiftelsen och Linc. Athera påbörjade nyligen kliniska fas

Stockholm December 3, 2015 Athera Biotechnologies AB, a privately held biopharmaceutical company focused on developing a new antibody against cardiovascular diseases, has completed a 24 million SEK financing from a consortium led by The Foundation for Baltic and East European Studies (Östersjöstiftelsen), Industrifonden and Linc Invest. Athera Biotechnologies AB develops novel products for risk assessment and treatment of CVD. The company was founded in 2002 to exploit findings made by Professors Johan Frostegard and Ulf de Faire on the critical role of phospholipid antibodies (aPL) in the inflammatory process of cardiovascular disease.

Anders Bergman is the Vice President, IP/Legal department at Athera Biotechnologies. Research Interest.
Gas oven

Karolinska Development AB Name. Athera Biotechnologies AB. Address, c/o Regus Norra Bantorget Olof Palmes Gata 29, 4Th Floor 111 22 Stockholm. MomsNr.

Athera Biotechnologies AB 14 maj 2019 Läkemedelsbolaget Athera Biotechnologies avslutade i veckan en emission om totalt 55 Mkr där Industrifonden, Östersjöstiftelsen och Title: Genetic aspects of risk markers. Participating partner(s):. Karolinska Institutet, Athera Biotechnologies AB, Uppsala University.
Fralsning buddhism

tidningen kollega kontakt
pixel 4a
hur tar man ur en orre
euro 5 euro 4
hus till salu vårgårda
lediga jobb odeshogs kommun
hitta revisor

Athera Biotechnologies AB. F-skatt. Ja, registrerad för F-skatt. Org. nummer. 556620-6859. Datum för upprättande. 2002-02-18. Antal anställda. 1. Aktiekapital.

2019-05-21 About Athera Biotechnologies . Athera develops anti-inflammatory medicine to treat vascular disease and conditions with major medical requirements, with a focus on the pharmaceutical candidate ATH3G10. The main shareholders are Industrifonden, Östersjöstiftelsen and Linc AB. Athera has just now completed a new share issue with Sciety. Stockholm December 3, 2015 Athera Biotechnologies AB, a privately held biopharmaceutical company focused on developing a new antibody against cardiovascular diseases, has completed a 24 million SEK financing from a consortium led by The Foundation for Baltic and East European Studies (Östersjöstiftelsen), Industrifonden and Linc Invest. Athera Biotechnologies AB - Org.nummer: 5566206859.